Thyroid Nodule (Benign)

Endocrinology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
CellFX® Percutaneous ElectrodeN/A1 trial
Active Trials
NCT06117085Completed30Est. Nov 2024

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Pulse BiosciencesCellFX® Percutaneous Electrode

Clinical Trials (1)

Total enrollment: 30 patients across 1 trials

NCT06117085Pulse BiosciencesCellFX® Percutaneous Electrode

CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules

Start: Apr 2023Est. completion: Nov 202430 patients
N/ACompleted

Related Jobs in Endocrinology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space